Market Outlook

Prostate cancer is the most common cancer among men in developed countries. Hormonal agents are the main treatment for prostate cancer and are routinely used throughout the course of the disease. Zytiga (Johnson & Johnson/Janssen Biotech/Janssen-Cilag/AstraZeneca’s abiraterone) and Xtandi (Pfizer/Astellas Pharma’s enzalutamide) are cornerstone treatments of metastatic castrate-resistant prostate cancer (mCRPC) and several clinical trials are evaluating their role in earlier stages of the disease. The late-phase pipeline for mCRPC has also become more dynamic with four PARP inhibitors: AstraZeneca’s Lynparza (olaparib), Clovis Oncology’s Rubraca (rucaparib), Tesaro/Janssen Biotech’s Zejula (niraparib), and Pfizer’s Talzenna (talazoparib); an immune checkpoint inhibitor, Roche/Genentech/Chugai’s Tecentriq (atezolizumab); a kinase inhibitor, Array BioPharma/Roche/Genentech /Chugai’s ipatasertib; and a radioligand therapy, Endocyte’s 177Lu-PSMA-617, entering Phase III development.

Questions Answered

What factors are driving and constraining market growth?

Which new classes of agents will emerge over the forecast period, and what impact will they have on the overall market?

How is prostate cancer currently managed, and how will treatment practices change?

What is the clinical and commercial potential of late-phase pipeline products, and what will be their likely positioning in the market? How will new market entrants fare through 2027?

What are the actionable remaining unmet needs affecting the management of prostate cancer?

What are the key drug development and therapeutic opportunities?

Product Description

Disease Landscape & Forecast: Comprehensive market intelligence providing world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Markets covered:United States, France, Germany, Italy, Spain, United Kingdom, and Japan.

Primary research: More than 20 country-specific interviews with thought-leading medical oncologists, supported by survey data collected for this and other DRG research.

Key companies: Johnson & Johnson, Janssen Biotech, Janssen-Cilag, AstraZeneca, Pfizer, Astellas Pharma, Sanofi, Roche, Tesaro, Clovis Oncology, Endocyte.Key drugs: Xtandi (enzalutamide), Zytiga (abiraterone), Erleada (apalutamide), Xofigo (radium-223), Jevtana (cabazitaxel), docetaxel, Yonsa (abiraterone acetate), Lynparza (olaparib), Rubraca (rucaparib), Talzenna (talazoparib), Zejula (niraparib), Tecentriq (atezolizumab), 177Lu-PSMA-617.


Related Reports

Prostate Cancer | Landscape & Forecast | Disease Landscape & Forecast

Prostate cancer is the most common cancer among men in developed countries. Hormonal agents are the mainstay of treatment for prostate cancer and are routinely used across lines. Zytiga...

View Details

Prostate Cancer | Current Treatment | Detailed, Expanded Analysis (US)

Hormonal therapies have dominated the treatment of prostate cancer for the past decade. Zytiga (Janssen, generics) and Xtandi (Medivation / Astellas Pharma), initially approved for metastatic cas...

View Details

Prostate Cancer | Epidemiology | Extrapolated Worldwide Coverage

DRG’s extended worldwide coverage is the first and only evidence-based data set of epidemiological forecasts for key prostate cancer patie...

View Details

Prostate Cancer | Current Treatment | Detailed, Expanded Analysis: Treatment Sequencing (US)

KEY BENEFITS AND USES Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting. Drill down into...

View Details